Chemotherapy drugs are used to treat dozens of conditions beyond cancer, including autoimmune diseases, blood disorders, severe organ inflammation, and neurological conditions like multiple sclerosis. The common thread is that these drugs suppress the immune system or slow rapidly dividing cells, which makes them useful whenever the body’s own immune response is causing harm.
The doses used for non-cancer conditions are typically far lower than what oncology patients receive. Methotrexate, one of the most widely prescribed examples, is given at 7.5 to 25 milligrams per week for autoimmune diseases compared to 1 to 5 grams per week in cancer therapy. That difference helps explain why side effects, while still real, tend to be more manageable outside of oncology.
Rheumatoid Arthritis and Psoriasis
Methotrexate is the single most common chemotherapy drug used for non-cancer purposes. It has been a cornerstone treatment for rheumatoid arthritis and severe psoriasis for decades. In cancer, it works by blocking an enzyme cells need to copy DNA, which kills fast-growing tumor cells. Its exact mechanism in autoimmune disease is actually still unknown, according to the drug’s FDA label, but the effect is clear: it calms overactive immune responses that drive joint inflammation and skin cell overproduction.
For rheumatoid arthritis, the typical starting dose is 7.5 milligrams taken once a week, with gradual increases until symptoms improve. Doses above 20 milligrams per week raise the risk of serious side effects like bone marrow suppression. For psoriasis, the range is 10 to 25 milligrams weekly, with a ceiling of 30 milligrams. These are oral tablets taken on a single day each week, not daily medications. Most people stay on methotrexate long-term if it works for them, often combined with folic acid supplements to reduce side effects like nausea and mouth sores.
Lupus and Kidney Inflammation
Cyclophosphamide, a powerful chemotherapy drug, is a standard treatment for severe lupus, particularly when the disease attacks the kidneys. Lupus nephritis, the kidney complication of lupus, can lead to organ failure if the immune assault isn’t stopped quickly. The initial treatment phase, called induction, typically lasts three to six months and aims to push the disease into remission.
Two main dosing approaches exist. The traditional regimen involves monthly intravenous infusions for six or seven cycles. A European protocol uses lower doses given every two weeks for six total doses, with comparable remission rates but fewer side effects. Studies show that roughly 75 to 90 percent of patients with proliferative lupus nephritis achieve at least a partial response with cyclophosphamide induction. Once remission is reached, patients switch to gentler maintenance medications to keep the disease quiet.
Blood Vessel Inflammation (Vasculitis)
Vasculitis is a group of conditions where the immune system attacks blood vessel walls, potentially damaging the kidneys, lungs, and nerves. One serious form, ANCA-associated vasculitis, has been treated with cyclophosphamide since the therapy dramatically improved survival rates decades ago. About 90 percent of patients achieve remission within 12 months of starting treatment, with a typical time to remission of around four months.
Research has shown that lower cumulative doses work just as well as higher ones for inducing remission, with the added benefit of fewer infections and less bone marrow suppression. Patients receiving lower doses had roughly half the rate of white blood cell depletion and significantly fewer urinary tract infections. Kidney function improved in both groups over the first two years regardless of dose. This has shifted treatment toward using the minimum effective amount, reducing the long-term risks that come with these drugs, including a higher chance of infections and, with prolonged use, secondary cancers.
Multiple Sclerosis
Several drugs originally developed as chemotherapy agents now treat relapsing-remitting multiple sclerosis, the most common form of the disease. In MS, the immune system strips away the protective coating around nerve fibers in the brain and spinal cord, causing episodes of numbness, weakness, vision problems, and fatigue.
Cladribine, originally a leukemia drug, is now classified as a high-efficacy treatment for highly active MS. It works by depleting specific white blood cells called lymphocytes that drive the immune attacks on nerve tissue. In clinical trials, about 22 percent of patients on cladribine experienced significant lymphocyte depletion, compared to 2 percent on placebo, reflecting the drug’s potent immune-suppressing effect. Other drugs in this category include alemtuzumab and rituximab, both of which target specific immune cells. These treatments are generally reserved for patients whose MS is aggressive or hasn’t responded to first-line therapies.
Bone Marrow and Stem Cell Transplants
Chemotherapy plays an essential role in stem cell transplants, even when the transplant itself is treating a non-cancerous condition like sickle cell disease or severe aplastic anemia. Before donor stem cells can be infused, the patient’s existing bone marrow needs to be prepared through a process called conditioning. This serves three purposes: clearing out the diseased or malfunctioning marrow, making physical space for the new donor cells to settle in, and suppressing the patient’s immune system enough that it won’t reject the transplanted cells.
Conditioning regimens range from full-intensity (myeloablative), which essentially wipes out the existing marrow, to reduced-intensity protocols that are less toxic but still create enough room for engraftment. The choice depends on the patient’s age, overall health, and the specific disease being treated. Full-intensity conditioning carries more short-term risk but may be necessary for certain conditions.
Aplastic Anemia
Aplastic anemia occurs when the bone marrow stops producing enough blood cells. In many cases, this happens because the immune system mistakenly attacks stem cells in the marrow. Treatment for serious cases relies on immunosuppressive drugs that are also used in transplant medicine and oncology, including cyclosporine and antithymocyte globulin. These medications pull back the immune assault on the marrow, allowing stem cell production to recover. For younger patients with a matched donor, a stem cell transplant (preceded by chemotherapy conditioning) may offer a more definitive solution.
Why the Same Drugs Work for Different Diseases
The connection between all these uses comes down to what chemotherapy drugs actually do at a cellular level. They suppress rapidly dividing cells and dampen immune activity. Cancer involves uncontrolled cell growth, so high doses destroy tumor cells. Autoimmune diseases involve an overactive immune system attacking the body’s own tissues, so lower doses quiet that response without the devastating side effects of full oncology regimens.
This is why the same drug can appear on both a cancer treatment plan and a prescription for arthritis. The intent, dose, and duration are different, but the underlying biology being targeted overlaps. If your doctor prescribes a medication that you recognize as a “chemo drug,” the context matters enormously. A weekly 10-milligram methotrexate tablet for psoriasis is a fundamentally different treatment experience than the gram-level doses used in leukemia protocols. Side effects still exist, including potential liver strain, increased infection risk, and nausea, but they’re proportional to the much lower doses involved.